Benefits and risks of add-on therapies for Alzheimer's disease

Neurodegenerative Disease Management

Volumn 5, Issue 5, 2015, Pages 445-462

  Magierski, Radoslaw ^a   Sobow, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Alzheimer's disease; antioxidants; cholinesterase inhibitor; combination therapy; memantine; mild cognitive impairment; vitamins

Indexed keywords

ANTIOXIDANT; CHOLINESTERASE INHIBITOR; MEMANTINE; NUTRACEUTICAL; VITAMIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DIFFUSE LEWY BODY DISEASE; GINKGO BILOBA; HUMAN; MONOTHERAPY; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; REVIEW;

EID: 85051687019     PISSN: 17582024     EISSN: 17582032     Source Type: Journal    
DOI: 10.2217/nmt.15.39     Document Type: Review

References (149)

1. Matthews FE, Arthur A, Barnes LE et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 382(9902), 1405-1412 (2013).
2. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer's disease. Arch. Med. Res. 43(8), 600-608 (2012).
3. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology 80(21), 1989-1996 (2013).
4. Costa N, Ferlicoq L, Derumeaux-Burel H et al. Comparison of informal care time and costs in different age-related dementias: a review. Biomed. Res. Int. 2013, 852368 (2013).
5. Sansoni J, Anderson KH, Varona LM, Varela G. Caregivers of Alzheimer's patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Ann. Ig. 25(3), 235-246 (2013).
6. van der Lee J, Bakker TJ, Duivenvoorden HJ, Droës RM. Multivariate models of subjective caregiver burden in dementia: a systematic review. Ageing Res. Rev. 15, 76-93 (2014).
7. Levy K, Lanctôt KL, Farber SB, Li A, Herrmann N. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden Drugs Aging 29(3), 167-179 (2012).
8. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of costeffectiveness analyses. Drugs 72(6), 789-802 (2012).
9. Rosenthal SL, Kamboh MI. Late-onset Alzheimer's disease genes and the potentially implicated pathways. Curr. Genet. Med. Rep. 2, 85-101 (2014).
10. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 77(1), 43-51 (2015).
11. Naj AC, Jun G, Reitz C et al. Effects of multiple genetic loci on age at onset in late-onset alzheimer disease: a genome-wide association study. JAMA Neurol. 71(11), 1394-1404 (2014).
12. Liu Y, Yu JT, Wang HF et al. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and metaanalysis. J. Neurol. Neurosurg. Psychiatry 86(2), 127-134 (2015).
13. Ritchie C, Smailagic N, Noel-Storr AH et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev. 6, CD008782 (2014).
14. Höglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E. Alzheimer's disease-recent biomarker developments in relation to updated diagnostic criteria. Clin. Chim. Acta. doi:10.1016/j. cca.2015.01.041 (2015) (Epub ahead of print).
15. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 280-292 (2011).
16. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 270-279 (2011).
17. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 263-269 (2011).
18. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007).
19. Dubois B, Feldman HH, Jacova C et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13(6), 614-629 (2014).
20. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 76(Pt A), 27-50 (2014).
21. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6(4), 37 (2014).
22. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloidbased immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev. Clin. Immunol. 10(3), 405-419 (2014).
23. Tan CC, Yu JT, Wang HF et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 41(2), 615-631 (2014).
24. Nelson PT, Alafuzoff I, Bigio EH et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71(5), 362-381 (2012).
25. Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J. Psychiatry Neurosci. 38(1), 6-23 (2013).
26. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL. The intersection of amyloid and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res. Rev. 12(3), 757-763 (2013).
27. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82(4), 756-771 (2014).
28. Parnetti L, Chiasserini D, Andreasson U et al. Changes in CSF acetyl-and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Acta Neurol. Scand. 124(2), 122-129 (2011).
29. Darreh-Shori T, Hosseini SM, Nordberg A. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. J. Alzheimers Dis. 39(2), 423-440 (2014).
30. Schneider LS, Mangialasche F, Andreasen N et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J. Intern. Med. 275(3), 251-283 (2014).
31. Madhusoodanan S, Ting MB. Pharmacological management of behavioral symptoms associated with dementia. World J. Psychiatry 4(4), 72-79 (2014).
32. Sobow T. Combination treatments in Alzheimer's disease: risks and benefits. Expert Rev. Neurother. 10(5), 693-702 (2010).
33. Francis PT, Parsons CG, Jones RW. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev. Neurother. 12(11), 1351-1365 (2012).
34. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 9(3), 326-331 (2013).
35. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox. Res. 24(3), 358-369 (2013).
36. Koola MM, Buchanan RW, Pillai A et al. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr. Res. 157(1-3), 84-89 (2014).
37. Lopes JP, Tarozzo G, Reggiani A, Piomelli D, Cavalli A. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav. 3(2), 67-74 (2013).
38. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. In vitro galantaminememantine co-application: mechanism of beneficial action. Neuropharmacology 51(7-8), 1181-1191 (2006).
39. Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J. Clin. Pharmacol. 46(7 Suppl. 1), 8S-16S (2006).
40. Wenk GL, Quack G, Moebius HJ, Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 66(12), 1079-1083 (2000).
41. Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol. 18(2), 81-85 (2003).
42. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann. Pharmacother. 38(9), 1389-1394 (2004).
43. Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients. CNS Neurosci. Ther. 19(2), 91-97 (2013).
44. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin. Pharmacokinet. 52(4), 225-241 (2013).
45. Poblador-Plou B, Calderón-Larranãga A, Marta-Moreno J et al. Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry 14, 84 (2014).
46. Bauer K, Schwarzkopf L, Graessel E, Holle R. A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatr. 14, 10 (2014).
47. Howes LG. Cardiovascular effects of drugs used to treat Alzheimer's disease. Drug Saf. 37(6), 391-395 (2014).
48. Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medicationrelated falls in the elderly: causative factors and preventive strategies. Drugs Aging 29(5), 359-376 (2012).
49. Bloch F, Thibaud M, Dugué B, Brèque C, Rigaud AS, Kemoun G. Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J. Aging Health 23(2), 329-346 (2011).
50. Chen Y, Zhu LL, Zhou Q. Effects of drug pharmacokinetic/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients. Ther. Clin. Risk Manag. 10, 437-448 (2014).
51. Oderda LH, Young JR, Asche CV, Pepper GA. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann. Pharmacother. 46(7-8), 917-928 (2012).
52. Muir SW, Gopaul K, Montero Odasso MM. The role of cognitive impairment in fall risk among older adults: a systematic review and meta-analysis. Age Ageing 41(3), 299-308 (2012).
53. Hsu CL, Nagamatsu LS, Davis JC, Liu-Ambrose T. Examining the relationship between specific cognitive processes and falls risk in older adults: a systematic review. Osteoporos. Int. 23(10), 2409-2424 (2012).
54. Kearney FC, Harwood RH, Gladman JR, Lincoln N, Masud T. The relationship between executive function and falls and gait abnormalities in older adults: a systematic review. Dement. Geriatr. Cogn. Disord. 36(1-2), 20-35 (2013).
55. Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A et al. Donepezil improves gait performance in older adults with mild Alzheimer's disease: a Phase II clinical trial. J. Alzheimers Dis. 43(1), 193-199 (2015).
56. Beauchet O, Launay CP, Allali G et al. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. BMC Neurol. 13, 184 (2013).
57. Beauchet O, Launay CP, Allali G, Annweiler C. Changes in gait variability with antidementia drugs: a systematic review and meta-analysis. CNS Drugs 28(6), 513-518 (2014).
58. Epstein NU, Guo R, Farlow MR, Singh JP, Fisher M. Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. Drugs Aging 31(2), 125-129 (2014).
59. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J. Am. Geriatr. Soc. 59(6), 1019-1031 (2011).
60. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291, 317-324 (2004).
61. Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis. Assoc. Disord. 20, 255-262 (2006).
62. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis. Assoc. Disord. 20, 263-268 (2006).
63. van Dyck CH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am. J. Geriatr. Psychiatry. 14(5), 428-437 (2006).
64. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67, 57-63 (2006).
65. Araki T, Wake R, Miyaoka T et al. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area. Int. J. Geriatr. Psychiatry 29(9), 881-889 (2014).
66. Shuan-Haim JR, Pass MD, Patel S, Patel S, Lee P, Smith J. P1-377 Safety, tolerability, and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease. Neurobiol. Aging 25(Suppl. 2), S205 (2004).
67. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract. 60(1), 110-118 (2006).
68. Riepe MW, Adler G, Ibach B, Weinkauf B, Gunay I, Tracik F. Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study. Prim. Care Companion J. Clin. Psychiatry. 8(5), 258-263 (2006).
69. Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Dement. Geriatr. Cogn. Disord. 23(5), 301-306 (2007).
70. Shua-Haim J, Smith J, Picard F et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin. Drug Investig. 28(6), 361-374 (2008).
71. Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int. J. Geriatr. Psychiatry. 25(4), 419-426 (2010).
72. Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr. Med. Res. Opin. 26(2), 263-269 (2010).
73. Han HJ, Kwon JC, Kim JE et al. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease. Eur. Neurol. 73(1-2), 23-28 (2015).
74. Hamuro A. Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease. Aust. NZ J. Psychiatry 47(6), 583 (2013).
75. Matsuzono K, Hishikawa N, Ohta Y et al. Combination therapy of cholinesterase inhibitor (Donepezil or Galantamine) plus memantine in the Okayama Memantine Study. J. Alzheimers Dis. 45(3), 771-780 (2015).
76. Kano O, Ito H, Takazawa T et al. Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil. Neuropsychiatr. Dis. Treat. 9, 259-265 (2013).
77. Grossberg GT, Manes F, Allegri RF et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 27(6), 469-478 (2013).
78. Gareri P, Putignano D, Castagna A et al. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study. J. Alzheimers Dis. 41(2), 633-640 (2014).
79. Shao ZQ. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. Int. J. Clin. Exp. Med. 8(2), 2944-2948 (2015).
80. de Oliveira FF, Bertolucci PH, Chen ES, Smith Mde A. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease. J. Neurol. Sci. 336(1-2), 103-108 (2014).
81. Peters O, Lorenz D, Fesche A et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J. Nutr. Health Aging 16(6), 544-548 (2012).
82. Howard R, McShane R, Lindesay J et al. Donepezil and memantine for moderate-tosevere Alzheimer's disease. N. Engl. J. Med. 366(10), 893-903 (2012).
83. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement. Geriatr. Cogn. Disord. 33(2-3), 164-173 (2012).
84. Choi SH, Park KW, Na DL et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr. Med. Res. Opin. 27(7), 1375-1383 (2011).
85. Han HJ, Kim BC, Lee JY et al. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients. Dement. Geriatr. Cogn. Disord. 34(3-4), 167-173 (2012).
86. Kornhuber J, Schmidtke K, Frolich L et al. Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement. Geriatr. Cogn. Disord. 27(5), 404-417 (2009).
87. Portela Romero M, Pombo Romero J, Bugarín González R, Tasende Souto M, Represa Veiga S. [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia]. Rev. Esp. Salud. Publica. 79(6), 665-672 (2005).
88. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 5(1), 83-89 (2008).
89. Schneider LS, Insel PS, Weiner MW, Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch. Neurol. 68(1), 58-66 (2011).
90. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 3, CD005593 (2006).
91. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst. Rev. CD003154 (2006).
92. Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S. Antidementia drug use among communitydwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study. Int. Clin. Psychopharmacol. 29(4), 216-223 (2014).
93. Vidal JS, Lacombe JM, Dartigues JF et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis. Assoc. Disord. 22(2), 125-130 (2008).
94. Tifratene K, Sakarovitch C, Rouis A, Pradier C, Robert P. Mild cognitive impairment and anti-Alzheimer disease medications: a cross sectional study of the French National Alzheimer Databank (BNA). J. Alzheimers Dis. 38(3), 541-549 (2014).
95. Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K. Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers. J. Am. Geriatr. Soc. 57(4), 686-690 (2009).
96. Tricco AC, Soobiah C, Berliner S et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 185(16), 1393-1401 (2013).
97. Jones R, Sheehan B, Phillips P et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease-a multicentre RCT. Trials 10, 57 (2009).
98. Farlow MR, Salloway S, Tariot PN et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, doubleblind study. Clin. Ther. 32, 1234-1251 (2010).
99. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer. Dis. Assoc. Disord. 22, 209-221 (2008).
100. Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80, 600-607 (2009).
101. Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and metaanalysis. Int. J. Neuropsychopharmacol. 18(5), pii: pyu115. (2014).
102. Atri A, Rountree SD, Lopez OL, Doody RS. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener. Dis. 10(1-4), 170-174 (2012).
103. Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur. J. Clin. Pharmacol. 69(7), 1467-1475 (2013).
104. Bohlken J, Weber S, Rapp MA, Kostev K. Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis. Int. Psychogeriatr. 27(8), 1335-1342 (2015).
105. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 9(3), 338-345 (2013).
106. Schmidt R, Hofer E, Bouwman FH et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur. J. Neurol. 22(6), 889-898 (2015).
107. Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8(7), 613-618 (2009).
108. Johansson C, Ballard C, Hansson O et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int. J. Geriatr. Psychiatry 26(2), 206-213 (2011).
109. Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(10), 969-977 (2010).
110. Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open. 4(7), e005158 (2014).
111. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst. Rev. 3, CD006504 (2012).
112. Wang HF, Yu JT, Tang SW et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J. Neurol. Neurosurg. Psychiatry 86(2), 135-143 (2015).
113. Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement. Geriatr. Cogn. Disord. 20(6), 338-344 (2005).
114. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst. Rev. 4, CD004746 (2013).
115. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst. Rev. 5, CD004744 (2013).
116. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 6(9), 782-792 (2007).
117. Lorrio S, Negredo P, Roda JM, Garciá AG, López MG. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain Res. 1254, 128-137 (2009).
118. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers. Res. Ther. 5(Suppl. 1), S5 (2013).
119. Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail Oxid. Med. Cell. Longev. 2014, 427318 (2014).
120. Galasko DR, Peskind E, Clark CM et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch. Neurol. 69(7), 836-841 (2012).
121. Annweiler C, Beauchet O. Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D. Drugs Aging 29(2), 81-91 (2012).
122. Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease-input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials 12, 230 (2011).
123. Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst. Rev. 11, CD002854 (2012).
124. Dysken MW, Guarino PD, Vertrees JE et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimers Dement. 10(1), 36-44 (2014).
125. Dysken MW, Sano M, Asthana S et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311(1), 33-44 (2014).
126. Quinn JF, Raman R, Thomas RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304(17), 1903-1911 (2010).
127. McGuinness B, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst. Rev. 7, CD007514 (2014).
128. Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer's dementia. Front. Aging Neurosci. 6, 282 (2014).
129. Fariás GA, Guzmán-Martínez L, Delgado C, Maccioni RB. Nutraceuticals: a novel concept in prevention and treatment of Alzheimer's disease and related disorders. J. Alzheimers Dis. 42(2), 357-367 (2014).
130. Mecocci P, Tinarelli C, Schulz RJ, Polidori MC. Nutraceuticals in cognitive impairment and Alzheimer's disease. Front. Pharmacol. 5, 147 (2014).
131. Shea TB, Remington R. Nutritional supplementation for Alzheimer's disease Curr. Opin. Psychiatry 28(2), 141-147 (2015).
132. Canevelli M, Adali N, Kelaiditi E et al. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomedicine 21(6), 888-892 (2014).
133. Wade AG, Farmer M, Harari G et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin. Interv. Aging 9, 947-961 (2014).
134. Aguirre E, Woods RT, Spector A, Orrell M. Cognitive stimulation for dementia: a systematic review of the evidence of effectiveness from randomised controlled trials. Ageing Res. Rev. 12(1), 253-262 (2013).
135. Tokuchi R, Hishikawa N, Matsuzono K et al. Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease. Geriatr. Gerontol. Int. doi:10.1111/ggi.12488 (2015) (Epub ahead of print).
136. Matsuzono K, Hishikawa N, Takao Y et al. Combination benefit of cognitive rehabilitation plus donepezil for Alzheimer's disease patients. Geriatr. Gerontol. Int. doi:10.1111/ggi.12455 (2015) (Epub ahead of print).
137. Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res. Ther. 2(6), 34 (2010).
138. Clegg A, Relton C, Young J, Witham M. Improving recruitment of older people to clinical trials: use of the cohort multiple randomised controlled trial design. Age Ageing 44(4), 547-550 (2015).
139. Peters KR, Lynn Beattie B, Feldman HH, Illes J. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. Prog. Neurobiol. 110, 114-123 (2013).
140. Benzinger TL, Blazey T, Jack CR Jr et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl Acad. Sci. USA 110(47), E4502-E4509 (2013).
141. Moulder KL, Snider BJ, Mills SL et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res. Ther. 5(5), 48 (2013).
142. Mills SM, Mallmann J, Santacruz AM et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev. Neurol. (Paris) 169(10), 737-743 (2013).
143. Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol. Aging 31(8), 1481-1492 (2010).
144. Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu. Rev. Clin. Psychol. 9, 621-648 (2013).
145. Nordberg A. Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res. Ther. 3(6), 34 (2011).
146. Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC. Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimers Res. Ther. 6(9), 87 (2014).
147. Merlo Pich E, Jeromin A, Frisoni GB et al. Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology Alzheimers Res. Ther. 6(4), 51 (2014).
148. Rosini M, Simoni E, Minarini A, Melchiorre C. Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem. Res. 39(10), 1914-1923 (2014).
149. Simoni E, Daniele S, Bottegoni G et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem. 55(22), 9708-9721 (2012).